Background: There is an interesting growing evidence for a relation between bronchiolitis and vitamin D. This suggests a possible benefit from Vitamin D therapy to children with bronchiolitis. Methods: We performed a double-blind, randomized clinical trial on 89 infants with bronchiolitis. Patients were randomized to receive vitamin D or placebo. Results: The intervention group, which received vitamin D therapy, had significant improvement in 3 parameters: The mean time taken for resolution of the disease, the mean time taken for the improvement of oral feeding and the duration of hospitalization. All these outcomes in the intervention group (vitamin D) were significantly better than the control (placebo) group with p 0.001, 0.05 and 0.01 respectively. Our study supported the efficacy of vitamin D therapy in bronchiolitis. Conclusion: This double-blinded, randomized placebo controlled trial of vitamin D supplementation 100 IU/kg daily in Egyptian children with bronchiolitis found a clinically and statistically significant reduction in hospitalization with rapid recovery of the disease. Our study suggested that short term supplementation with Vitamin D given daily during the course of illness, starting from day one, may help in resolution of bronchiolitis. Trial of Vitamin D Supplementation in Infants with Bronchiolitis: A Randomized, Double-Blind, Placebo-Controlled Study. Available from: https://www.researchgate.net/publication/274699981_Trial_of_Vitamin_D_Supplementation_in_Infants_with_Bronchiolitis_A_Randomized_Double-Blind_Placebo-Controlled_Study [accessed Jun 3, 2015].

Background: There is an interesting growing evidence for a relation between bronchiolitis and vitamin D. This suggests a possible benefit from Vitamin D therapy to children with bronchiolitis. Methods: We performed a double-blind, randomized clinical trial on 89 infants with bronchiolitis. Patients were randomized to receive vitamin D or placebo. Results: The intervention group, which received vitamin D therapy, had significant improvement in 3 parameters: The mean time taken for resolution of the disease, the mean time taken for the improvement of oral feeding and the duration of hospitalization. All these outcomes in the intervention group (vitamin D) were significantly better than the control (placebo) group with p 0.001, 0.05 and 0.01 respectively. Our study supported the efficacy of vitamin D therapy in bronchiolitis. Conclusion: This double-blinded, randomized placebo controlled trial of vitamin D supplementation 100 IU/kg daily in Egyptian children with bronchiolitis found a clinically and statistically significant reduction in hospitalization with rapid recovery of the disease. Our study suggested that short term supplementation with Vitamin D given daily during the course of illness, starting from day one, may help in resolution of bronchiolitis. Trial of Vitamin D Supplementation in Infants with Bronchiolitis: A Randomized, Double-Blind, Placebo-Controlled Study. Available from: https://www.researchgate.net/publication/274699981_Trial_of_Vitamin_D_Supplementation_in_Infants_with_Bronchiolitis_A_Randomized_Double-Blind_Placebo-Controlled_Study [accessed Jun 3, 2015].

Background: There is an interesting growing evidence for a relation between bronchiolitis and vitamin D. This suggests a possible benefit from Vitamin D therapy to children with bronchiolitis. Methods: We performed a double-blind, randomized clinical trial on 89 infants with bronchiolitis. Patients were randomized to receive vitamin D or placebo. Results: The intervention group, which received vitamin D therapy, had significant improvement in 3 parameters: The mean time taken for resolution of the disease, the mean time taken for the improvement of oral feeding and the duration of hospitalization. All these outcomes in the intervention group (vitamin D) were significantly better than the control (placebo) group with p 0.001, 0.05 and 0.01 respectively. Our study supported the efficacy of vitamin D therapy in bronchiolitis. Conclusion: This double-blinded, randomized placebo controlled trial of vitamin D supplementation 100 IU/kg daily in Egyptian children with bronchiolitis found a clinically and statistically significant reduction in hospitalization with rapid recovery of the disease. Our study suggested that short term supplementation with Vitamin D given daily during the course of illness, starting from day one, may help in resolution of bronchiolitis. Trial of Vitamin D Supplementation in Infants with Bronchiolitis: A Randomized, Double-Blind, Placebo-Controlled Study. Available from: https://www.researchgate.net/publication/274699981_Trial_of_Vitamin_D_Supplementation_in_Infants_with_Bronchiolitis_A_Randomized_Double-Blind_Placebo-Controlled_Study [accessed Jun 3, 2015].

Background: There is an interesting growing evidence for a relation between bronchiolitis and vitamin D. This suggests a possible benefit from Vitamin D therapy to children with bronchiolitis. Methods: We performed a double-blind, randomized clinical trial on 89 infants with bronchiolitis. Patients were randomized to receive vitamin D or placebo. Results: The intervention group, which received vitamin D therapy, had significant improvement in 3 parameters: The mean time taken for resolution of the disease, the mean time taken for the improvement of oral feeding and the duration of hospitalization. All these outcomes in the intervention group (vitamin D) were significantly better than the control (placebo) group with p 0.001, 0.05 and 0.01 respectively. Our study supported the efficacy of vitamin D therapy in bronchiolitis. Conclusion: This double-blinded, randomized placebo controlled trial of vitamin D supplementation 100 IU/kg daily in Egyptian children with bronchiolitis found a clinically and statistically significant reduction in hospitalization with rapid recovery of the disease. Our study suggested that short term supplementation with Vitamin D given daily during the course of illness, starting from day one, may help in resolution of bronchiolitis. Trial of Vitamin D Supplementation in Infants with Bronchiolitis: A Randomized, Double-Blind, Placebo-Controlled Study. Available from: https://www.researchgate.net/publication/274699981_Trial_of_Vitamin_D_Supplementation_in_Infants_with_Bronchiolitis_A_Randomized_Double-Blind_Placebo-Controlled_Study [accessed Jun 3, 2015].

Abstract: Objective: To evaluate the clinical outcome and advantages of the Percutaneous plate fixation for complex distal tibial fractures using locking compression plate- distal tibial plate (LCP-DTP). Design: This is a prospective case series study Setting: Urban, level I trauma center. Patients and methods: 27 adult patients; who met the inclusion criteria; with closed traumatic distal tibia with or without fibular fractures were treated using minimally invasive plate osteosynthesis MIPO technique with LCP-DTP. According to the AO fracture classification, there were 12 AO 43A fractures, 15 AO 43B fractures. The fibula was fractured in 15 patients and it was fixed in all of them. Main outcome measurements: Peri-operative complications following percutaneous fixation of the distal tibia as infection, deformity, leg length discrepancy, ankle joint function, bony union and metal failure within one year after surgery. Results: This study included 27 adult patients with traumatic fracture distal third tibia, 21 of them were males and 6 females. They were followed up for a period ranging from 14 to 19 months with an average of 16. None of the patients developed early peri-operative complications. Deep venous thrombosis occurred in 3 patients, who were treated medically, residual loss of a few degrees ankle motion in 6 and late infection related to the proximal screws was also observed in 3 obese uncontrolled diabetic patients. Union was achieved in all of them within 12- 20 weeks with an average of 16. Conclusions: MIPO for the distal tibia using the LCP-DTP is safe and effective in the treatment of complex distal tibial fractures.

Background: There is growing evidence for a gut-brain connection associated with autism spectrum disorders (ASD). This suggests a potential benefit from introduced digestive enzymes for children with ASD. Methods: We performed a double-blind, randomized clinical trial on 101 children with ASD (82 boys and 19 girls) aged from 3 to 9 years. ASD patients were diagnosed according to DSM-IV-TR diagnostic criteria. Structured interviews of at least one hour each both with the parents and the child were performed. Later on, another two hours-session was conducted applying the Childhood Autism Rating Scale (CARS). ASD patients were randomized to receive digestive enzymes or placebo. Results: The ASD group receiving digestive enzyme therapy for 3 months had significant improvement in emotional response, general impression autistic score, general behavior and gastrointestinal symptoms. Our study demonstrated the usefulness of digestive enzyme in our population of ASD patients. Conclusion: Digestive enzymes are inexpensive, readily available, have an excellent safety profile, and have mildly beneficial effects in ASD patients. Depending on the parameter measured in our study; we propose digestive enzymes for managing symptoms of ASD. Digestive enzyme therapy may be a possible option in treatment protocols for ASD in the future A randomized, Placebo-Controlled Trial of Digestive Enzymes in Children with Autism Spectrum Disorders. Available from: https://www.researchgate.net/publication/273063768_A_randomized_Placebo-Controlled_Trial_of_Digestive_Enzymes_in_Children_with_Autism_Spectrum_Disorders [accessed Jun 3, 2015].

Background: There is growing evidence for a gut-brain connection associated with autism spectrum disorders (ASD). This suggests a potential benefit from introduced digestive enzymes for children with ASD. Methods: We performed a double-blind, randomized clinical trial on 101 children with ASD (82 boys and 19 girls) aged from 3 to 9 years. ASD patients were diagnosed according to DSM-IV-TR diagnostic criteria. Structured interviews of at least one hour each both with the parents and the child were performed. Later on, another two hours-session was conducted applying the Childhood Autism Rating Scale (CARS). ASD patients were randomized to receive digestive enzymes or placebo. Results: The ASD group receiving digestive enzyme therapy for 3 months had significant improvement in emotional response, general impression autistic score, general behavior and gastrointestinal symptoms. Our study demonstrated the usefulness of digestive enzyme in our population of ASD patients. Conclusion: Digestive enzymes are inexpensive, readily available, have an excellent safety profile, and have mildly beneficial effects in ASD patients. Depending on the parameter measured in our study; we propose digestive enzymes for managing symptoms of ASD. Digestive enzyme therapy may be a possible option in treatment protocols for ASD in the future A randomized, Placebo-Controlled Trial of Digestive Enzymes in Children with Autism Spectrum Disorders. Available from: https://www.researchgate.net/publication/273063768_A_randomized_Placebo-Controlled_Trial_of_Digestive_Enzymes_in_Children_with_Autism_Spectrum_Disorders [accessed Jun 3, 2015].